Sandoz announced today that its biosimilar pegfilgrastim has been accepted for review by the European Medicines Agency (EMA).
Sandoz announced today that its biosimilar pegfilgrastim has been accepted for review by the European Medicines Agency (EMA).
Sandoz’s product, like its reference, the EU-approved Neulasta, is a long-acting granulocyte-colony stimulating factor. Pegfilgrastim is used in the prophylaxis of chemotherapy-induced febrile neutropenia, and many patients and physicians prefer the drug to short-acting filgrastim because of its less-frequent administration.
"Our goal is to improve patient access to important biologic medicines and the EMA [filing] acceptance of our biosimilar pegfilgrastim is a move towards doing just that," said Mark Levick, MD, PhD, global head of development, biopharmaceuticals. "If approved, we look forward to supporting cancer patients, healthcare professionals, and [payers] with our biosimilar pegfilgrastim."
Sandoz previously withdrew an application for its pegfilgrastim from the EMA; in February, Sandoz notified the Committee for Medicinal Products for Human Use (CHMP) that it would rescind its application for the proposed biosimilar that it had planned to market as Zioxtenzo.
CHMP had noted 2 main concerns about Zioxtenzo, neither of which Sandoz was able to resolve in the timeframe allowed by the regulator: first, study results were unable to demonstrate that concentrations of pegfilgrastim in the blood were the same in patients taking the biosimilar and the reference Neulasta. Second, Sandoz’s proposed manufacturing site had not received a certificate of Good Manufacturing Practice, and an inspection of the facility was still outstanding. “At the time of the withdrawal, the company had not demonstrated that Zioxtenzo is highly similar to Neulasta,” according to the EMA.
Sandoz also experienced disappointment for the drug in the United States; in July 2016, the FDA issued a complete response letter for the proposed biosimilar. Sandoz determined that it would conduct an additional pharmacokinetic study, and reported in early 2017 that it would resubmit its application to the FDA in 2018.
In addition to Sandoz, numerous other biosimilar developers are seeking US and EU regulatory approval for pegfilgrastim molecules; Cinfa Biotech, USV, Mylan—Biocon, Coherus, Gideon Richter, Apotex, and Adello are engaged in developing prospective biosimilars for the top-selling Neulasta.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.